FAST NEWS: CStone drug approved for treatment of advanced non-small cell lung cancer
The Latest: Drug maker CStone Pharmaceuticals (2616.HK) announced on Tuesday its Pralsetinib, also known by the brand name Gavreto, was approved by China’s drug regulator as a first-line treatment for…
Recent Articles
RELATED ARTICLES
-
Stock disconnect triggers investor exodus from CStone Pharma
2616.HK -
AstraZeneca pays hefty price for Chinese weight-loss drug
AZN.US
-
ArriVent wows investors with promising China-developed lung cancer treatment
AVBP.US
-
BeiGene still bleeding red ink despite blockbuster drug
BGNE.US 6160.HK 688235.SHG
-
Akeso marks profit milestone with swift rights issue
9926.HK
